17 October 2025
17 October 2025
The AAM¡¯s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics do not change.
Novo Nordisk will now run a Phase III trial for zaltenibart in the rare blood disorder, PNH.
The investment is part of AstraZeneca¡¯s wider $50bn outlay to bolster manufacturing in the US.
The partnership is in accordance with a White House Executive Order aimed at enhancing affordable access
Adcytherix has set a target to file for an IND and clinical trial applications in Canada, the UK, and the EU by the end of 2025.
With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe¡¯s most dynamic biotech ecosystems - despite lacking a big pharma anchor and facing persistent funding gaps.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
